Norovirus full genome sequencing is challenging due to sequence heterogeneity between 16 genomes. Previous methods have relied on PCR amplification, which is problematic due to 17 primer design, and RNASeq which non-specifically sequences all RNA in a stool specimen, 18 including host and bacterial RNA. 19 Target enrichment uses a panel of custom-designed 120-mer RNA baits which are 20 complementary to all publicly available norovirus sequences, with multiple baits targeting 21 each position of the genome, thus overcoming the challenge of primer design. Norovirus 22 30 164 samples were tested in parallel with conventional PCR genotyping of the capsid shell 31 domain. 164/164 samples were successfully sequenced, compared to 158/164 that were 32 amplified by PCR. Four of the samples that failed capsid PCR had low titres, suggesting 33 target enrichment is more sensitive than gel-based PCR. Two samples failed PCR due to 34 primer mismatches; target enrichment uses multiple baits targeting each position, thus 35 accommodating sequence heterogeneity between norovirus genomes.
genomes are enriched from stool RNA extracts to minimise sequencing non-target RNA. 23 SureSelect target enrichment and Illumina sequencing was used to sequence full genomes 24 from 507 norovirus positive stool samples with RT-qPCR Ct values 10-43. Sequencing on an 25 Illumina MiSeq in batches of 48 generated on average 81% on-target-reads per sample and 26 100% genome coverage with >12,000-fold read depth. Samples included genotypes GI.1, 27 GI.2, GI.3, GI.6, GI.7, GII.1, GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, GII.13, GII.14 and GII.17 . Once 28 outliers are accounted for, we generate over 80% genome coverage for all positive samples, 29 regardless of Ct value.
Introduction 37 Norovirus is a leading cause of outbreaks of acute gastroenteritis (1, 2) with an estimated 38 prevalence of 20% in cases of acute gastroenteritis in developed countries (3) and a high 39 financial burden in healthcare settings associated with ward and hospital closures (4). In 40 countries where rotavirus vaccine has been introduced, norovirus is now the leading cause 41 of medically-attended gastroenteritis in children (5, 6) . 42 Norovirus has a 7.5kb single stranded RNA genome, organised into 3 open reading frames; 43 ORF1, ORF2 and ORF3. ORF1 encodes a non-structural polyprotein which is cleaved post-44 translationally and includes the RNA-dependent RNA polymerase. ORF2 encodes the major 45 structural capsid protein, which is divided into shell (S) and protruding (P) domains. The P 46 domain has two subdomains, P1 and P2. P2 is the most exposed antigenic site and contains 47 immunogenic epitopes; consequently it has the greatest sequence variation. ORF3 codes for 48 a minor capsid protein. 49 50 Comparison of viral genetic sequences allows linking of previously unrecognised 51 transmission events or exclusion of cases from an outbreak. Traditionally, 52 norovirus genotyping has involved polymerase chain reaction (PCR) amplification and 53 capillary sequencing of partial regions of the polymerase and capsid sequences, followed by 54 additional sequencing of the P2 region for outbreak investigations. This is a labour intensive 55 process requiring several rounds of PCR and sequencing, each requiring genogroup or 56 genotype specific primers and only yields partial genome sequences at the end. Moreover, 57 whilst the P2 domain can identify linked outbreak events with 64-73% specificity (assuming 58 bootstrap support >70 or <70, respectively), the full capsid sequence can identify linked 59 outbreak events with 100% specificity (7) and thus is more informative. 60 Whole genome sequencing simplifies investigation of norovirus molecular epidemiology by 61 generating all the regions of interest in one step, thus allowing identification of the 62 genotype, variant type and full capsid sequence; negating the need for sequential PCR and 63 sequencing reactions. However, unlike bacteria, which can be isolated in pure culture, 64 norovirus culture is difficult (8) GI.7, GII.1, GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, GII.13, GII.14 and GII.17 , as detailed in Table   84 1. The presence of norovirus was verified in all samples using a multiplex norovirus GI and 85 GII-specific one-step reverse-transcription real-time PCR (RT-qPCR); the primer and probe 86 sequences and cycling conditions have been previously described (manuscript submitted to 87 J Clin Virol). For 78/507 samples provided by one of the centres, the presence of norovirus 88 RNA was not verified in the re-extracted residual specimen; for these samples the Ct value corresponds to the original extract used as part of diagnostic service. The RT-qPCR 90 cycle threshold (Ct) value is used in this study as a semi-quantitative indicator of viral titre. 91 All specimens were residual diagnostic specimens obtained from patients with confirmed 92 norovirus infections. Specimens were submitted to the UCL Infection DNA Bank for use in 93 this study. All samples were supplied to the study in an anonymised form; the use of these 94 specimens for research was approved by the NRES Committee London -Fulham (REC RNA extracts were concentrated to 11 µl using a vacuum centrifuge at 65 o C prior to first 110 strand cDNA synthesis. First strand cDNA was synthesised using random primers and 111 SuperScript III (SS III, Life Technologies) as per manufacturer's instructions. Briefly, 1 µl of 112 10mM (each) dNTP mix and 1 µl of 3 µg/ml random primers were incubated with 11 µl RNA 113 for five minutes at 65 °C to anneal primers to RNA template, followed by incubation on ice 114 for 1 minute. RNA-primer templates were mixed with 4 µl 5x first strand buffer, 1 µl 0.1M 115 DTT, 1 µl RNase OUT and 1 µl SS III at 25 °C for 5 minutes followed by cDNA synthesis at 50 116 °C for 1 hour and enzyme inactivation at 70 °C for 15 minutes. Second strand cDNA was 117 synthesised using Second Strand cDNA Synthesis kit (NEB) as per manufacturer's instruction. 118 Briefly, 20 µl first strand cDNA was incubated with 48 µl water, 8 µl 10x 2 nd strand buffer 119 and 4 µl 2 nd strand enzyme mix at 16 °C for 2.5 hours. Double stranded cDNA was purified Overlapping 120-mer RNA baits complementary to and spanning the length of 622 norovirus 125 partial or complete genomes from Genbank were designed using an in-house PERL script. 126 Briefly, a 120 nucleotide sliding window is scanned along each reference genome at 127 intervals of 10 nucleotides. If the 120-mer is sufficiently different to other 120-mer 128 sequences in the baitset (as assessed by BLAT (21)), it is retained in the baitset; otherwise 129 that 120-mer is discarded. In this way, the baitset spans the diversity in all of the included 130 reference genomes. The baitset is available upon request. The reference genomes included 131 samples from polymerase genotypes GI.P1, GI.P2, GI.P3, GI.P4, GI.P6, GI.P8, GI.Pb, GI.Pc, 132 GI.Pd, GI.Pf, GII.P1, GII.P2, GII.P3, GII.P4, GII.P5, GII.P6, GII.P7, GII.P8, GII.P11, GII.P12, 133 GII.P15, GII.P16, GII.P17, GII.P18, GII.P21, GII.P22, GII.Pc, GII.Pe, GII.Pg, GII.Pp, GIII, GIV, GV 134 and GVI and capsid genotypes GI.1, GI.2, GI.3, GI.4, GI.5, GI.6, GI.8, GII.2, GII.3, GII.4, GII.5, 135 GII.6, GII.7, GII.8, GII.10, GII.11, GII.12, GII.13, GII.14, GII.15, GII.16, GII.17, GII.18, GII.21, 
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Overall sequencing outcomes 202 Since the aim was to generate full genome sequences, we defined the cut-off for sequencing 203 success as >90% coverage of the full norovirus genome with >100-fold mean read depth to 204 ensure a robust consensus sequence. Samples that met only one of these criterions were 205 categorised as "sub-optimal", and those which did not meet either criteria were considered 206 a "fail".
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Of 507 samples across all sampled genotypes, 453 (89%) passed; i.e. had >90% genome 208 coverage and >100-fold read depth (Table 1 , Figure 2 , Figure A1 ). However in total, 93% of 209 samples had a genome coverage of >90% at any depth. A median of 81.22% of the total 210 sequencing reads generated for each sample mapped to the norovirus genome, referred to 211 as the % on-target-reads (% OTR). On average, 100% of the full genome was covered (% 212 genome coverage) with median read depth of 12,227-fold (Table 1) . 213 There was no significant difference in % OTR (P = 0.127), mean read depth (P = 0.398) or % 214 genome coverage (P = 0.203) between norovirus genotypes (Figure 3 (a-c) ). 215 A significant correlation was found between % OTR and read depth (R = 0.757, P <0.001, 216 Figure A2 ) and between PCR Ct value and (i) % OTR (R = −0.536, P <0.001), (ii) read depth (R 217 = −0.468, P <0.001) and (iii) % genome coverage (R = −0.223, P <0.001) (Figure 3 (d-f) ). It 218 follows that there is a significant difference in PCR Ct value between samples that passed 219 compared to those that were sub-optimal (P <0.001) or failed (P <0.001) with median Ct Figure A3 ), which were known to have had processing problems during cDNA preparation. 234 Six of the 16 samples with Ct <30 and genome coverage <80% had sufficient residual 235 specimen to be repeated; all of these passed on repeat. 236 Three samples (highlighted in Figure A3 , detailed in RT-qPCR primer target region, the seven genome sequences were aligned to the RT-qPCR 257 primer and probe sequences used to generate the Ct value. There were no mismatches in 258 the primer or probe sites ( Figure A5 ), suggesting they are genuinely low titre samples and 259 confirming the sensitivity of the method for low titre samples. (Table A3 ). 266 Two of the failed samples, with Ct values 20 and 27, had mismatches at the genotyping 267 primer sites ( Figure A6 ) which accounts for genotyping failure in these instances. 268 The remaining four of the six samples that failed genotyping had Ct values >30 (range 31-269 37), which suggests the genotyping PCR is less sensitive than sequencing by target Figure A7 and Figure A8 ). The mapped regions do not correspond to PCR amplicon 277 sites. 278 Mixed infections 279 Three (3/507) samples were identified as having sequences from more than one genotype 280 during the assembly pipeline (Table A4 ). For two of the samples, the mixed infections were 281 evident during the "mapping to reference list" step of the de novo pipeline (Figure 1) 
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